The Paracelsus Medical University is a private university located in Salzburg municipality, Austria and Nuremberg, Germany.

During the past decade, PMU Salzburg conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 8 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 5 clinical trials were completed. i.e. 250% of trials that started reached the finish line.

Out of the total clinical trials conducted in "PMU Salzburg" #1 sponsor was "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 5 trials, followed by "Abbott Medical Optics" with 2 trials sponsored, "Hoffmann-La Roche" with 2 trials sponsored, "Shire" with 2 trials sponsored and "Bristol-Myers Squibb" with 2 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "PMU Salzburg" #1 collaborator was "Amgen" with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator and "Nektar Therapeutics" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "PMU Salzburg" are "Multiple Myeloma" (2 trials), "Carcinoma, Non-Small-Cell Lung" (1 trials), "Corneal Astigmatism" (1 trials), "Endothelial Cell Loss, Corneal" (1 trials) and "Fabry Disease" (1 trials). Many other conditions were trialed in "PMU Salzburg" in a lesser frequency.

Most popular intervention types in "PMU Salzburg" are "Drug" (7 trials), "Device" (4 trials), "Biological" (2 trials), "Other" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "Paclitaxel" (2 trials), "5-fluorouracil" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody" (1 trials) and "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody" (1 trials). Other intervention names were less common.

The vast majority of trials in "PMU Salzburg" are 14 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "PMU Salzburg". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in PMU Salzburg, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in PMU Salzburg, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".

PMU Salzburg has several departments that took part in Clinical trials: "Department of Sports Medicine, Prevention and Rehabilitation Paracelsus Medical University" - 10 trials